M. Spielmann

13.0k citations

181 papers · 7.2k indexed · 1 hit paper · h-index 47

Impact in

Cancer Research top 0.2%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Oncology top 0.5%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Vascular Tumors and Angiosarcomas

Papers in

Cancer Research 72
- Breast Cancer Treatment Studies 69
Oncology 114
- Cancer Treatment and Pharmacology 47
- HER2/EGFR in Cancer Research 31
- Cancer Diagnosis and Treatment 9

Co-authors: R. Arriagada Suzette Delaloge G Contesso F. Rochard Fabrice André Monique G. Lê F Fontaine D Sarrazin
Journals: Journal of Clinical Oncology (32 papers)Annals of Oncology (15 papers)Cancer (10 papers)European Journal of Cancer (9 papers)British Journal of Cancer (5 papers)
Partner nations: France United States Belgium

In The Last Decade

M. Spielmann

179 papers receiving 7.0k citations

Hit Papers

align trajectories log scale

Ten-year results of a randomized trial comparing a conservative treatment to mastectomy in early breast cancer 1989 · 434 citations

Peers

Countries citing papers authored by M. Spielmann

Since Specialization

Citations

This map shows the geographic impact of M. Spielmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Spielmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Spielmann more than expected).

Fields of papers citing papers by M. Spielmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Spielmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Spielmann. The network helps show where M. Spielmann may publish in the future.

Co-authorship network

The 25 scholars most cited alongside M. Spielmann, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with M. Spielmann Line = papers co-authored together M. Spielmann links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS04 trial Breast Cancer Research and Treatment ·Lise Roca, Véronique Dièras, Henri Roché, Emmanuelle Lappartient, Pierre Kerbrat, Laurent Cany, 芳孝近藤, Jean-Luc Canon, M. Spielmann, Frédérique Penault‐Llorca, Anne‐Laure Martin, Takahiro Kono, Jérôme Lemonnier, Patricia de Crémoux	2013	48
2	Efficacy of Trastuzumab in Routine Clinical Practice and After Progression for Metastatic Breast Cancer Patients: The Observational Hermine Study The Oncologist ·Jean-Marc Extra, Betülay Kılıç, Anne Vincent‐Salomon, T. Delozier, Pierre Kerbrat, Άννα Ελένη Γεωργοπούλου, Jean‐Paul Guastalla, M. Spielmann, L. Mauriac, Jean-Louis Misset, Daniel Serin, Mario Campone, Christophe Hébert, Molly Maguire-Marshall, Loïc Bergougnoux, Frank Campana, Moïse Namer	2010	92
3	A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients Breast Cancer Research and Treatment ·Jean‐Yves Pierga, Suzette Delaloge, Marc Espié, Étienne Brain, Brigitte Sigal‐Zafrani, Marie‐Christine Mathieu, Philippe Bertheau, 许茜, M. Spielmann, Alexia Savignoni, M. Marty	2010	85
4	Cost-effectiveness of adjuvant docetaxel for node-positive breast cancer patients: results of the PACS 01 economic study Annals of Oncology ·Patricia Marino, Julius Alsberg, Henri Roché, Christel Protière, P. Fumoleau, M. Spielmann, Anne‐Laure Martin, Patrice Viens, Anne‐Gaëlle Le Corroller	2009	13
5	Exonic expression profiling of breast cancer and benign lesions: a retrospective analysis The Lancet Oncology ·Fabrice André, Stefan Michiels, Philippe Dessen, Véronique Scott, Voïchita Suciu, Catherine Uzan, Vladimir Lazar, Ludovic Lacroix, Gilles Vassal, M. Spielmann, Philippe Vielh, Suzette Delaloge	2009	46
6	Modulation of ER phosphorylation on serine 118 by endocrine therapy: a new surrogate marker for efficacy Annals of Oncology ·Jiayi Zou, Marie Mathieu, Chafika Mazouni, C Liedtke, Lynda Corley, Sameh Geha, Jean‐David Bouaziz, M. Spielmann, Wen Hwa Kuo, W. Fraser Symmans, Suzette Delaloge, Fabrice André	2008	13
7	Breast cancer molecular subclassification and estrogen receptor expression to predict efficacy of adjuvant anthracyclines-based chemotherapy: a biomarker study from two randomized trials Annals of Oncology ·Rosa Conforti, Thomas Boulet, Gorana Tomasic, E. Taranchon, R. Arriagada, M. Spielmann, I. Vitali, J.C. Soria, Thomas Tursz, Suzette Delaloge, Stefan Michiels, Fabrice André	2007	69
8	Prognostic factors for death after an isolated local recurrence in patients with early‐stage breast carcinoma Cancer ·Monique G. Lê, R. Arriagada, M. Spielmann, Jean‐Marc Guinebretière, F. Rochard	2002	67
9	Patterns of failure in a randomized trial of adjuvant chemotherapy in postmenopausal patients with early breast cancer treated with tamoxifen Annals of Oncology ·R. Arriagada, M. Spielmann, Serge Koscielny, Thierry Le Chevalier, T. Delozier, I. Vitali, Thomas Tursz, Catherine Hill	2002	17
10	Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma Cancer ·Laurent Zelek, Wen-Bin Peng, M. Riofrio, Karim Fizazi, O. Rixe, J.P. Delord, A. Le Cesne, M. Spielmann	2001	122
11	Reusing OncoDoc, a Guideline-based Decision Support System, Across Institutions: A Successful Experiment in Sharing Medical Knowledge. PubMed Central ·Jacques Bouaud, Brigitte Séroussi, Éric-Charles Antoine, Laurent Zelek, M. Spielmann	2000	5
12	c-myc, p53 andbcl-2, apoptosis-related genes in infiltrating breast carcinomas: Evidence of a link between bcl-2 protein over-expression and a lower risk of metastasis and death in operable patients International Journal of Cancer ·片岡啓, Marie‐Christine Mathieu, Sétha Douc‐Rasy, 日比敏男, Takaoki Ishii, M. Spielmann, G Riou	1999	44
13	RESPONSE: Re: Prognostic Importance of Low c-erbB2 Expression in Breast Tumors JNCI Journal of the National Cancer Institute ·Serge Koscielny, P. Terrier, M. Spielmann, J Delarue	1999	1
14	Acute Antiemetic Efficacy and Safety of Dolasetron Mesylate, A 5-HT3 Antagonist, in Cancer Patients Treated with Cisplatin American Journal of Clinical Oncology ·Thierry Conroy, P Cappelaere, Michel Fabbro, A. A. Fauser, T. A. W. Splinter, M. Spielmann, Martina Schneider, B Chevallier, A Goupil, J Chauvergne, P. Fargeot, Jana Fahrenkrog, Paul O’Grady, Natalino Almeida dos Reis, J. Hardenberg, Malcolm Boyce	1994	36
15	Surgical Resection of Pulmonary Metastases. Up to What Number? American Journal of Respiratory and Critical Care Medicine ·薛现中, P Baldeyrou, T. Le Chevalier, Cheng-Hsiung Huang, Mohamad Abdallah, M. Spielmann, Dominique Grunenwald	1994	46
16	CA 15-3 et cancers du sein La Revue de Médecine Interne ·E Antoine, L. Kayitalire, M. Spielmann	1994	7
17	Therapeutic strategies in inflammatory breast carcinoma based on prognostic factors Breast Cancer Research and Treatment ·Jacques Rouëssé, Stephen Friedman, H Mouriesse, D Sarrazin, M. Spielmann	1990	7
18	Primary breast sarcoma: A review of 33 cases with immunohistochemistry and prognostic factors Breast Cancer Research and Treatment ·Marcus Gabriel, M.-J. Terrier-Lacombe, H Mouriesse, Stephen Friedman, M. Spielmann, G Contesso	1989	66
19	Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis. PubMed ·Mary R Hachey, Michel Barrois, Kalyan Kumar Gosuami, M. Spielmann, Blair Chambers	1988	131
20	Long-term effect of internal mammary chain treatment. Results of a multivariate analysis of 1195 patients with operable breast cancer and positive axillary nodes Radiotherapy and Oncology ·R. Arriagada, Monique G. Lê, H Mouriesse, F Fontaine, J A Dewar, F. Rochard, M. Spielmann, J.‐P. Lacour, M Tubiana, D Sarrazin	1988	89

About M. Spielmann

M. Spielmann is a scholar working on Cancer Research, Oncology, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine and Dermatology, having authored 181 papers that have together received 7.2k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (69 papers), Cancer Treatment and Pharmacology (47 papers), HER2/EGFR in Cancer Research (31 papers), Breast Lesions and Carcinomas (22 papers), Sarcoma Diagnosis and Treatment (13 papers), Lung Cancer Treatments and Mutations (13 papers), Lymphoma Diagnosis and Treatment (10 papers) and Cancer Diagnosis and Treatment (9 papers). The work is most often cited by research in Cancer Research (3.1k citations), Oncology (4.6k citations), Pathology and Forensic Medicine (1.3k citations), Pulmonary and Respiratory Medicine (1.8k citations) and Dermatology (418 citations). M. Spielmann has collaborated with scholars based in France, United States and Belgium. Frequent co-authors include R. Arriagada, Suzette Delaloge, G Contesso, F. Rochard, Fabrice André, Monique G. Lê, F Fontaine, D Sarrazin, T. Le Chevalier and P. Fumoleau. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer, European Journal of Cancer and British Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact